scholarly journals Influence of Emergency Declaration Over Coronavirus Disease 2019 on Plasma Glucose Control of Patients With Diabetes Mellitus

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A347-A347
Author(s):  
Takuya Watanabe ◽  
Tetsuya Takamizawa ◽  
Junichi Okada ◽  
Eijiro Yamada ◽  
Tsugumichi Saito ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Glucose ◽  
Glucose Control ◽  
The State ◽  
The Self ◽  
State Of Emergency ◽  
Self Monitoring ◽  
Patients With Diabetes ◽  
The Mean ◽  
Hba1c Levels

Abstract COVID-19 pandemic poses problems that not only concern the economy but also the health of people all over the world. In Japan, despite the declaration of a “state of emergency”, no lockdown was implemented, and a request for self-restraint and avoidance of non-essential trips was instead issued. After a month, the state of emergency was lifted. Because patients with diabetes mellitus (DM) were forced to stay during the state of emergency, resulting in a lack of physical activity, concerns about their glycemic control were raised. Therefore, glycated hemoglobin (HbA1c) levels during different time periods were compared (May 2018, March 2019, June 2019, July 2019, May 2019, March 2020, June 2020, July 2020). We analyzed 165 patients with DM. The mean age of subjects was 67.8 + 11.5 years. Male comprised 67.3% of the participants. The mean body weight was 65.6 + 14.6 kg on July 2019 and 66.1 + 15.2 kg on July 2020. The mean body mass index (BMI) was 24.4 + 3.6 kg/m2 on July 2019 and 24.4 + 3.6 on July 2020. Patients with Type 2 DM (T2DM) comprised 90% of the participants, while the rest had T1DM. Mean duration of DM was 12.0 + 7.4 years. In order to assess the effect of the self-restraint on plasma glucose control, HbA1c levels during these periods were compared: May 2018, March 2019, June 2019, July 2019 (one year before COVID-19 pandemic.), and May 2019, March 2020, June 2020, July 2020 (The last three months during COVID-19). March 2020 is corresponded to a period before the request for self-restraint, while June and July 2020 corresponded to the periods right after the end of self-restraint. We also compared HbA1c levels between May 2019 and July 2020 using the Self-Monitoring of Blood Glucose (SMBG) to assess whether SMBG affected plasma glucose control during the period of self-restraint. HbA1c levels in May 2018, March 2019, June 2019, July 2019, May 2019, March 2020, June 2020, July 2020, were 7.32 + 1.23, 7.44 + 1.20, 7.16 + 1.06, 7.01 + 1.05, 7.23 + 1.06, 7.45 + 1.18, 7.15 + 10.7, and 7.11 + 1.17, respectively. Similarly, HbA1c levels between May 2019 without SMBG and May 2019 with SMBG were not statistically different. In this clinical study, we found that the request to avoid non-essential trips as a form of self-restraint during the country’s state of emergency did not affect plasma glucose control of patients with DM. We noted that the patients did not have signs of insulin resistance as their BMI on July 2019 and July 2020 were 24.4 + 3.6 and 24.4 + 3.6, respectively. Unexpectedly, the HbA1c levels were not affected by the absence or presence of SMBG. This could explain why HbA1c levels were not elevated, despite a temporarily sedentary lifestyle and a lack of exercise for a month. In addition, due to the self-restraint, the frequency of dining outside the house decreased, which could have contributed to the non-elevation of HbA1c levels.

scholarly journals Altered levels of fructosamine and glycated haemoglobin (HbA1c) in thyroid disorder patients without diabetes mellitus-A cross sectional study

Biomedicine ◽  
2021 ◽  
Vol 41 (1) ◽  
pp. 46-51
Author(s):  
G.Sajjan Sangamma ◽  
S. Sonoli Smita ◽  
Naveen Angadi
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Glycated Hemoglobin ◽  
Thyroid Disorder ◽  
Newly Diagnosed ◽  
Fasting Plasma ◽  
Significant Difference ◽  
The Mean ◽  
Hba1c Levels

Introduction and Aim:Co-existence of thyroid disorder and Diabetes Mellitus is no more a coincidence. The cause and impact of thyroid disorder on glucose levels or vice versa is a well -established fact.Hence in this study we wanted to know the glycemic status by estimating fructosamine and glycated hemoglobin of the newly diagnosed thyroid patients without diabetes mellitus. The aim of the study was to estimatefructosamine and glycated hemoglobin levels in newly diagnosed subclinical hypothyroid, clinical hypothyroid and hyper thyroid patients without diabetes mellitus. Material and Methods:Twenty cases of subclinical hypothyroid,30 cases of hypothyroid,30 cases of hyperthyroid  and 30 healthy participantswere included in the study. Fasting plasma glucose and thyroid profile was estimated in suspected cases of thyroid disorder and participants with fasting plasma glucose (FPG) more than 110 mg/dL were excluded from the study.The participants who were eligible for an inclusion criterion were estimated for fructosamine by nitro bluetetrazolium, (NBT) method andion-exchange high performance liquid chromatography was for glycated hemoglobin. Results:In Subclinical hypothyroid group there was a statistically significant increase in the mean fasting plasma glucose, fructosamine and glycated hemoglobin levels when compared with the controls.There was a significant increase in the mean fasting plasma glucose,fructosamine and glycated hemoglobin(HbA1c) levels in clinical hypothyroid group when compared with the controls.Pairwise comparison of FPG (p=0.001), fructosamine (p=0.001) and HbA1c (p=0.001) levels with controls showed a statistically significant difference.In clinical hyperthyroid group the mean FPG and HbA1c levels were high and low fructosamine levels when compared with the controls by one way ANOVA.Pairwise comparison of FPG (p=0.001), fructosamine levels (p=0.001) and HbA1c (p=0.001) levels (p=0.001) with controls showed a statistically significant difference. Conclusion: Unidentified hyperglycemia could have an impact on thyroid disorder leading to its complication.Hence a systematic approach to fructosamine testing(monitor the plasma glucose concentration over 2–3 weeks) as a routine test in thyroid disorder patients, needs to be considered.Also the management of hyperglycemia in thyroid patients without diabetes mellitus may prove  to be beneficial.  

Self-monitoring of blood glucose and perceived obstacles in Turkish patients with diabetes mellitus

2014 ◽  
Author(s):  
Ozlem Turhan Iyidir ◽  
Mustafa Unubol ◽  
Bulent Ogun Hatipoglu ◽  
Ceyla Konca Degertekin
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Self Monitoring ◽  
Patients With Diabetes ◽  
Turkish Patients

Model estimates of the results of diabetes patients using modern glucometers with tri-color technology for displaying test results

2019 ◽  
pp. 81-89
Author(s):  
Larisa Dmitrievna Popovich ◽  
Svetlana Valentinovna Svetlichnaya ◽  
Aleksandr Alekseevich Moiseev
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Economic Benefits ◽  
Test Results ◽  
Self Monitoring ◽  
Patients With Diabetes ◽  
The Impact

Diabetes – a disease in which the effect of the treatment substantially depends on the patient. Known a study showed that the use of glucometers with the technology of three-color display of test results facilitates self-monitoring of blood sugar and leads to a decrease in glycated hemoglobin (HbAlc). Purpose of the study: to modeling the impact of using of a glucometer with a color-coded display on the clinical outcomes of diabetes mellitus and calculating, the potential economic benefits of reducing the hospitalization rate of patients with diabetes. Material and methods. Based on data from two studies (O. Schnell et al. and M. Baxter et al.) simulation of the reduction in the number of complications with the use of a glucometer with a color indication. In a study by O. Schnell et al. a decrease of HbA1c by 0.69 percent is shown when using the considered type of glucometers, which was the basis of the model. Results. In the model, the use of a glucometer with a color-coded display for type 1 diabetes led to a decrease in the total number of complications by 9.2 thousand over 5 years per a cohort of 40 thousand patients with different initial levels of HbA1c. In a cohort of 40 thousand patients with type 2 diabetes, the simulated number of prevented complications was 1.7 thousand over 5 years. When extrapolating these data to all patients with diabetes included in the federal register of diabetes mellitus (FRD), the number of prevented complications was 55.4 thousand cases for type 1 diabetes and 67.1 thousand cases for type 2 diabetes. The possible economic effect from the use of the device by all patients with a diagnosis of diabetes, which are included in the FRD, estimated at 1.5 billion rubles for a cohort of patients with type 1 diabetes and 5.3 billion rubles for patients with type 2 diabetes. Conclusion. Improving the effectiveness of self-monitoring, which is the result of the use of glucometers with color indicators, can potentially significantly reduce the incidence of complications in diabetes and thereby provide significant economic benefits to society.

scholarly journals Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study

2020 ◽  
Vol 9 (7) ◽  
pp. 2275
Author(s):  
Juan J. Gorgojo-Martínez ◽  
Manuel A. Gargallo-Fernández ◽  
Alba Galdón Sanz-Pastor ◽  
Teresa Antón-Bravo ◽  
Miguel Brito-Sanfiel ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Real World ◽  
Primary Outcome ◽  
Baseline Hba1c ◽  
Real World Setting ◽  
Antihyperglycemic Therapy ◽  
The Mean ◽  
Hba1c Levels

The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibitor (SGLT-2i) therapy by switching to canagliflozin 300 mg/d (CANA300) in patients with T2DM. One cohort of SGLT2i-naïve patients with T2DM who were initiated on CANA100 and a second cohort of patients with prior background SGLT-2i therapy who switched to CANA300 were included in the study. The primary outcome of the study was the mean change in HbA1c over the follow-up time. In total, 583 patients were included—279 in the cohort of CANA100 (HbA1c 8.05%, weight 94.9 kg) and 304 in the cohort of CANA300 (HbA1c 7.51%, weight 92.0 kg). Median follow-up periods in both cohorts were 9.1 and 15.4 months respectively. CANA100 was associated to significant reductions in HbA1c (−0.90%) and weight (−4.1 kg) at the end of the follow-up. In those patients with baseline HbA1c > 8% (mean 9.25%), CANA100 lowered HbA1c levels by 1.51%. In the second cohort, patients switching to CANA300 experienced a significant decrease in HbA1c (−0.35%) and weight (−2.1 kg). In those patients with baseline HbA1c > 8% (mean 8.94%), CANA300 lowered HbA1c levels by 1.12%. There were significant improvements in blood pressure in both cohorts. No unexpected adverse events were reported. In summary, CANA100 (as an add-on therapy) and CANA300 (switching from prior SGLT-2i therapy) significantly improved several cardiometabolic parameters in patients with T2DM.

Nasal mucociliary clearance in patients with diabetes mellitus

1989 ◽  
Vol 103 (9) ◽  
pp. 853-855 ◽  
Author(s):  
W. L. Yue
Keyword(s):  
Diabetes Mellitus ◽  
Mucociliary Clearance ◽  
Mean Value ◽  
Nasal Disease ◽  
Patients With Diabetes ◽  
History Of ◽  
Insulin Dependent ◽  
Mucociliary Function ◽  
The Mean ◽  
Nasal Mucociliary Clearance

AbstractFifty insulin-dependent diabetics and 50 non-diabetics without a history of nasal disease have been studied for nasal problems including mucociliary function complicated by diabetes mellitus. For the diabetics, the mean value of nasal mucociliary clearance was considerably decreased and this was more often associated with dry noses but increased pH-values, both of which were higher than those for non-diabetics (p<0.05). As suggested in earlier literature, more aggressive nasal moistening therapy must be recommended for those patients presenting with these conditions in the light of systemic diabetic abnormalities.

Effect of Different Factors on Glycosylated Hemoglobin (HbA1c) Levels Among Diabetes Mellitus Patients

2021 ◽  
Vol 15 (12) ◽  
pp. 3513-3515
Author(s):  
Bader Alsuwayt
Keyword(s):  
Diabetes Mellitus ◽  
Glycated Hemoglobin ◽  
Glycosylated Hemoglobin ◽  
Diabetic Patients ◽  
Study Results ◽  
Patients With Diabetes ◽  
Insulin Use ◽  
Low Rate ◽  
Statin Use ◽  
Hba1c Levels

Aim: To describe the rate of the controlled level of glycosylated hemoglobin (HbA1c) among diabetes mellitus patients in Dammam city, Kingdom of Saudi Arabia (KSA). To assess the association between the status of HbA1c and the different patient-related factors namely: insulin use, metformin, dyslipidemia, and statin use. Methods: This cross-sectional study was performed at Security Forces Hospital, Dammam, KSA, between November 2020 and February 2021. A sample of two hundred known diabetic patients who were regularly followed up at the outpatient department (OPD) was selected randomly for the current study. Results: A very low rate (24%) of controlled HbA1C levels in patients with diabetes (type 1 DM and type 2 DM), The data showed that 85 % of all participants in our study are T2DM patients, while only 15% are T1DM patients, Our data showed that patients with dyslipidemia, hypothyroidism, or hypertension have a high level of uncontrolled HbA1C levels. Surprisingly, both dyslipidemia and statin use were predictors of uncontrolled HbA1C, Unexpectedly, non-metformin use has a protective effect toward controlling HbA1C, While insulin use is a strong predictor of uncontrolled HbA1C (OD 5.20). Conclusion: A low rate of controlled glycated hemoglobin (HbA1c) level among patients with diabetes (T1DM and T2DM) in our sample urges the need for immediate intervention to investigate and improve the current findings. Further investigations are needed to fully explain the high rate of uncontrolled HbA1c among insulin, metformin and statins users. Keywords: Glycated hemoglobin, HbA1c, Diabetes mellitus, Statins, Metformin.

Sign in / Sign up

Export Citation Format

Share Document